Home › Funds › RA CAPITAL MANAGEMENT, L.P. › PCVX

RA CAPITAL MANAGEMENT, L.P. position in PCVX

VAXCYTE INC · Health Care

RA CAPITAL MANAGEMENT, L.P. reported holding 11,474,599 shares of PCVX (VAXCYTE INC) in its Q2 2026 13F filing — a position valued at US$667.0M, representing 5.80% of its reported portfolio and ranking #4 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed PCVX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)11.47M sh
Reported value held$667.02M
Portfolio Weight5.80%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How RA CAPITAL MANAGEMENT, L.P.'s PCVX position evolved

RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in PCVX in Q3 2023 at 7,891,254 shares (US$402.3M). The position peaked in Q3 2024 at 8,689,190 shares, worth US$992.9M. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 11,474,599 shares valued at US$667.0M. Notable position changes include a 40% increase in Q1 2025 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 7.89M $402.30M New
Q4 2023 7.89M $495.57M Hold
Q1 2024 8.20M $560.40M Add
Q2 2024 8.20M $619.47M Hold
Q3 2024 8.69M $992.91M Add
Q4 2024 8.69M $711.30M Hold
Q1 2025 12.19M $460.26M Add
Q2 2025 11.97M $389.01M Reduce
Q3 2025 11.97M $431.01M Hold
Q4 2025 10.72M $494.83M Reduce
Q1 2026 11.47M $666.79M Add
Q2 2026 11.47M $667.02M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PCVX and 13F data

PCVX (VAXCYTE INC) is a Health Care company. 35 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PCVX

All PCVX fund holders →

FAQ

How long has RA CAPITAL MANAGEMENT, L.P. held PCVX?

RA CAPITAL MANAGEMENT, L.P. has disclosed PCVX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is RA CAPITAL MANAGEMENT, L.P.'s current position in PCVX?

As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 11.47M shares of PCVX (VAXCYTE INC), valued at $667.02M, representing 5.80% of its reported portfolio and ranking #4.

Has RA CAPITAL MANAGEMENT, L.P. been buying or selling PCVX?

In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in PCVX. The position peaked in Q3 2024 at 8.69M shares.

Which other funds hold PCVX?

Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.